Phase 2 N=80 Anti-Cytokine Therapy for Hemodialysis InflammatION
End-Stage Renal Disease
Primary: Safety and Tolerability of Anakinra, for Patients Receiving Maintenance Hemodialysis — 2.71; 2.74 events per patient-year
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=124 Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: Progression-free Survival by CYP2D6 Status in 2 Categories — 12.9; 6.9 months
Phase 2 N=42 Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma
Ganglioneuroblastoma · High Risk Neuroblastoma
Primary: Percentage of Participants With Unacceptable Toxicity — 0.0 percentage of patients
Phase 2 N=12 Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
Body Dysmorphic Disorders
Primary: Body Dysmorphic Disorder Modification of the Yale-Brown Obsessive Compulsive Disorder Scale — 18.42 score on a scale — p=<0.001
Phase 2 N=557 A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors
Melanoma · Renal Cell Carcinoma · Non Small Cell Lung Cancer
Primary: Part 1 Dose Escalation: Incidence of Dose-limiting Toxicity (DLT) During the DLT Evaluation Window — 0; 0; 0; 0 Participants
Phase 2 N=105 Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting · Multiple Sclerosis, Secondary Progressive · Multiple Sclerosis, Primary Progressive
Primary: Change in Cognitive Function as Assessed by the Symbol Digit Modalities Test (SDMT) — 0.145; 0.207; 0.163 score on a scale
Phase 2 N=18 Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia
Severe Aplastic Anemia · Bone Marrow Failure Syndromes
Primary: Is This Type of Transplantation for Severe Aplastic Anemia Feasible and Safe? — 18 Participants
Phase 2 N=15 Abdominal Binder to Treat Orthostatic Hypotension (OH) in Parkinson's Disease (PD)
Parkinson's Disease · Neurogenic Orthostatic Hypotension in Parkinson's Disease
Primary: Change in Mean Blood Pressure (mmHg) After 3 Minutes of Passive Orthostatic Challenge From Baseline, When Wearing an Elastic Abdominal Binder vs a Placebo Binder for 2…
Phase 2 N=199 A Study of BAY3427080 (NT-814) in the Treatment of Moderate to Severe Post-menopausal Vasomotor Symptoms
Menopause · Hot Flashes · Night Waking
Primary: Mean Change From Baseline in Mean Daily Frequency of Moderate and Severe Hot Flushes From Baseline to Week 4 — 11.82; 12.13; 14.55; 13.54 Hot flushes per day — p== 0.1946
Phase 2 N=71 SMART Trial: Intrapersonal and Interpersonal Stigma Reduction
Stigma, Social · Opioid Use · Opioid-use Disorder
Primary: Enacted Stigma (Intrapersonal) — 0.730 score on a scale — p=0.252
Phase 2 N=379 A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplantation
Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants
Phase 2 N=45 The Impact of Adjuvant Liquid Alginate on Endoscopic Ablation Therapy of Complicated Barrett's Esophagus
Barretts Esophagus With Dysplasia
Primary: Percentage of Patients With Successful Eradication — 45.5; 38.1; 36.4; 19.04 percentage of participants
Phase 2 N=23 Gene Therapy for Achromatopsia (CNGB3)
Achromatopsia
Primary: Number of Participants Meeting the Primary Outcome Defined as Any of the Below Events Occurring During the 6 Weeks Following Administration, at Least Possibly Related to…
Phase 2 N=28 Impact of Nuedexta on Bulbar Physiology and Function in ALS
Amyotrophic Lateral Sclerosis
Primary: Change in Dynamic Imaging Grade of Swallowing Toxicity — 3; 7 Participants — p=0.08
Phase 2 N=10 Letermovir Treatment for Refractory or Resistant Cytomegalovirus Infection
Cytomegalovirus Infections
Primary: Virological Response on Treatment Week 6 — 5 Participants